Companies › ModeX Therapeutics, An OPKO Health Company
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Infectious disease; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MDX2301 Monoclonal antibody against SARS-CoV-2 spike protein | – | Phase 1 | COVID -19 | Sep 2027 |
| MDX2003 | – | Phase 1 | Lymphoma | Jan 2028 |
| MDX2001 | – | Phase 1 | Biliary Tract Cancer | Aug 2028 |
| MDX2004 | – | Phase 1 | Advanced Tumors | Jun 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07445971 | MDX2301 | Phase 1 | COVID -19 | Infectious disease | Sep 2027 |
| NCT07249905 | MDX2003 | Phase 1 | Lymphoma | Oncology | Jan 2028 |
| NCT06239194 | MDX2001 | Phase 1 | Biliary Tract Cancer | Oncology | Aug 2028 |
| NCT07110584 | MDX2004 | Phase 1 | Advanced Tumors | Oncology | Jun 2031 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.